Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, announced Wednesday that it will offer 6.0 million shares at a range of $14 to $16. Assuming the stock prices at the midpoint, the company will have an initial market capitalization of $300 million. Merrill Lynch and Morgan Stanley are the joint book runners on the deal. Timing has yet to be determined.
